

Thierry Buclin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7486970/publications.pdf>

Version: 2024-02-01

261
papers

14,122
citations

22153
59
h-index

24982
109
g-index

279
all docs

279
docs citations

279
times ranked

14658
citing authors

#	ARTICLE	IF	CITATIONS
1	Parametric Approaches in Population Pharmacokinetics. Journal of Clinical Pharmacology, 2022, 62, 125-141.	2.0	17
2	Long-acting antiretrovirals: a new era for the management and prevention of HIV infection. Journal of Antimicrobial Chemotherapy, 2022, 77, 290-302.	3.0	47
3	Parametric and Nonparametric Methods in Population Pharmacokinetics: Experts' Discussion on Use, Strengths, and Limitations. Journal of Clinical Pharmacology, 2022, 62, 158-170.	2.0	9
4	Therapeutic drug monitoring of newer generation antiseizure medications at the point of treatment failure. Seizure: the Journal of the British Epilepsy Association, 2022, 94, 66-69.	2.0	4
5	Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19. Clinical Microbiology and Infection, 2022, 28, 1044-1046.	6.0	13
6	Model-based meta-analysis of salbutamol pharmacokinetics and practical implications for doping control. CPT: Pharmacometrics and Systems Pharmacology, 2022, , .	2.5	4
7	Therapeutic drug monitoring of cefepime in a non-critically ill population: retrospective assessment and potential role for model-based dosing. JAC-Antimicrobial Resistance, 2022, 4, dlac043.	2.1	5
8	Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study. Multiple Sclerosis Journal, 2021, 27, 475-478.	3.0	16
9	No renal dysfunction or salt and water retention in acute mountain sickness at 4,559 m among young resting males after passive ascent. Journal of Applied Physiology, 2021, 130, 226-236.	2.5	9
10	Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV. Clinical Pharmacokinetics, 2021, 60, 379-390.	3.5	4
11	Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs. European Journal of Clinical Pharmacology, 2021, 77, 979-987.	1.9	2
12	Case Report: Colchicine Toxicokinetic Analysis in a Poisoned Child Requiring Extracorporeal Life Support. Frontiers in Pediatrics, 2021, 9, 658347.	1.9	5
13	Seizure freedom and plasma levels of newer generation antiseizure medications. Acta Neurologica Scandinavica, 2021, 144, 202-208.	2.1	8
14	Pharmacokinetics of anti-infective agents during CytoSorb hemoadsorption. Scientific Reports, 2021, 11, 10493.	3.3	35
15	Dosing strategies of imipenem in neonates based on pharmacometric modelling and simulation. Journal of Antimicrobial Chemotherapy, 2021, , .	3.0	2
16	Ensuring Sufficient Trough Plasma Concentrations for Broad-Spectrum Beta-Lactam Antibiotics in Children With Malignancies: Beware of Augmented Renal Clearance!. Frontiers in Pediatrics, 2021, 9, 768438.	1.9	6
17	Compassionate Use of Letemovir in a 2-Year-Old Immunocompromised Child With Resistant Cytomegalovirus Disease. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 96-99.	1.3	10
18	Optimisation of vancomycin exposure in neonates based on the best level of evidence. Pharmacological Research, 2020, 154, 104278.	7.1	25

#	ARTICLE	IF	CITATIONS
19	Imatinib Uptake into Cells is Not Mediated by Organic Cation Transporters OCT1, OCT2, or OCT3, But is Influenced by Extracellular pH. <i>Drug Metabolism Letters</i> , 2020, 13, 102-110.	0.8	9
20	Therapeutic Drug Monitoring of Newer Antiepileptic Drugs: A Randomized Trial for Dosage Adjustment. <i>Annals of Neurology</i> , 2020, 87, 22-29.	5.3	30
21	Therapeutic Drug Monitoring of Targeted Anticancer Protein Kinase Inhibitors in Routine Clinical Use: A Critical Review. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 33-44.	2.0	25
22	Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV. <i>Aids</i> , 2020, 34, 103-108.	2.2	18
23	The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib. <i>Frontiers in Pharmacology</i> , 2020, 11, 177.	3.5	59
24	Validation and clinical application of a multiplex high performance liquid chromatography – tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020, 1157, 122160.	2.3	38
25	Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV. <i>Journal of Mass Spectrometry</i> , 2020, 55, e4506.	1.6	22
26	Impact of Genetic and Nongenetic Factors on Body Mass Index and Waist-Hip Ratio Change in HIV-Infected Individuals Initiating Antiretroviral Therapy. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofz464.	0.9	7
27	Influence of Drug-Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1037-1048.	3.5	5
28	Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1717-1728.	2.8	61
29	Sultiame pharmacokinetic profile in plasma and erythrocytes after single oral doses: A pilot study in healthy volunteers. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00558.	2.4	8
30	UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1125, 121733.	2.3	10
31	Gender medicine and oncology: report and consensus of an ESMO workshop. <i>Annals of Oncology</i> , 2019, 30, 1914-1924.	1.2	120
32	Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2690-2697.	3.0	23
33	Methods for Personalised Delivery Rate Computation for IV Administered Anesthetic Propofol. <i>Computational Biology</i> , 2019, , 369-397.	0.2	1
34	Development and validation of a multiplex UHPLC-MS/MS method for the determination of the investigational antibiotic against multi-resistant tuberculosis macozinone (PBTZ169) and five active metabolites in human plasma. <i>PLoS ONE</i> , 2019, 14, e0217139.	2.5	14
35	Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2022-2032.	2.4	7
36	Clindamycin clearance during Cytosorb® hemoadsorption: A case report and pharmacokinetic study. <i>International Journal of Artificial Organs</i> , 2019, 42, 258-262.	1.4	12

37	Complementary medicine use during cancer treatment and potential herb-drug interactions from a cross-sectional study in an academic centre. Scientific Reports, 2019, 9, 5078.	3.3	71
38	Polypharmacy, Drug-Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV. Open Forum Infectious Diseases, 2019, 6, ofz531.	0.9	38
39	Intravenous brivaracetam in status epilepticus: Correlation between loading dose, plasma levels and clinical response. Epilepsy Research, 2019, 149, 88-91.	1.6	36
40	Sub-picomolar quantification of PTH 1-34 in plasma by UHPLC-MS/MS after subcutaneous injection of teriparatide and identification of PTH 1-33, its degradation product. Journal of Pharmaceutical and Biomedical Analysis, 2019, 166, 205-212.	2.8	3
41	Multicenter Population Pharmacokinetic Study of Colistimethate Sodium and Colistin Dosed as in Normal Renal Function in Patients on Continuous Renal Replacement Therapy. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	12
42	Pharmacovigilance, h�movigilance, vaccinovigilance, t�ratovigilance����: quelles retomb�es impr�vues pour les patients, les intervenants de sant� et les syst�mes de soins�?. Anthropologie & Sant�, 2019, , .	0.2	0
43	LC�MS/MS method for the simultaneous analysis of seven antimalarials and two active metabolites in dried blood spots for applications in field trials: Analytical and clinical validation. Journal of Pharmaceutical and Biomedical Analysis, 2018, 154, 263-277.	2.8	33
44	Pregnancy outcomes in women on metformin for diabetes or other indications among those seeking teratology information services. British Journal of Clinical Pharmacology, 2018, 84, 568-578.	2.4	35
45	F44. AN ADD-ON TRIAL WITH N-ACETYL-CYSTEINE (NAC) IN EARLY PSYCHOSIS PATIENTS: TOWARDS BIOMARKER GUIDED TREATMENT. Schizophrenia Bulletin, 2018, 44, S236-S236.	4.3	0
46	Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1083, 124-136.	2.3	31
47	N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis. Schizophrenia Bulletin, 2018, 44, 317-327.	4.3	121
48	Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections. Journal of Antimicrobial Chemotherapy, 2018, 73, 3413-3422.	3.0	40
49	Levetiracetam circulating concentrations and response in status epilepticus. Epilepsy and Behavior, 2018, 88, 61-65.	1.7	13
50	Association of Patient Sex With Chemotherapy-Related Toxic Effects. JAMA Oncology, 2018, 4, 1003.	7.1	41
51	Comparison against current standards of a DNA aptamer for the label-free quantification of tobramycin in human sera employed for therapeutic drug monitoring. Journal of Pharmaceutical and Biomedical Analysis, 2018, 159, 341-347.	2.8	22
52	Ethical approval for multicenter cohort studies on drug exposure during pregnancy: A survey among members of the European Network of Teratology Information Services (ENTIS). Reproductive Toxicology, 2018, 80, 68-72.	2.9	3
53	Robustness analysis of personalised delivery rate computation for IV administered anesthetic. Smart Health, 2018, 9-10, 101-114.	3.2	7
54	Determination of nucleosidic/tidic reverse transcriptase inhibitors in plasma and cerebrospinal fluid by ultra-high-pressure liquid chromatography coupled with tandem mass spectrometry. Clinical Mass Spectrometry, 2018, 8, 8-20.	1.9	10

#	ARTICLE	IF	CITATIONS
55	Sensitive quantification of the somatostatin analog AP102 in plasma by ultra-high pressure liquid chromatography-tandem mass spectrometry and application to a pharmacokinetic study in rats. Drug Testing and Analysis, 2018, 10, 1448-1457.	2.6	2
56	Myoglobinuria in two patients with Duchenne muscular dystrophy after treatment with zoledronate: a case-report and call for caution. Neuromuscular Disorders, 2018, 28, 865-867.	0.6	10
57	Efficacy and safety of continuous infusions with elastomeric pumps for outpatient parenteral antimicrobial therapy (OPAT): an observational study. Journal of Antimicrobial Chemotherapy, 2018, 73, 2540-2545.	3.0	35
58	Pharmacokinetics of Pomalidomide in a Patient Receiving Hemodialysis Using a High-Cutoff Filter. American Journal of Kidney Diseases, 2017, 69, 553-554.	1.9	4
59	Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure. Cancer Chemotherapy and Pharmacology, 2017, 79, 215-218.	2.3	2
60	Renal Drug Transporters and Drug Interactions. Clinical Pharmacokinetics, 2017, 56, 825-892.	3.5	161
61	Guidance to develop individual dose recommendations for patients on chronic hemodialysis. Expert Review of Clinical Pharmacology, 2017, 10, 737-752.	3.1	11
62	Free and total plasma concentrations of elvitegravir/cobicistat during pregnancy and postpartum: a case report. British Journal of Clinical Pharmacology, 2017, 83, 2835-2838.	2.4	15
63	Adequate plasma drug concentrations suggest that amoxicillin can be administered by continuous infusion using elastomeric pumps. Journal of Antimicrobial Chemotherapy, 2017, 72, 2613-2615.	3.0	18
64	Antibiotic stability related to temperature variations in elastomeric pumps used for outpatient parenteral antimicrobial therapy (OPAT). Journal of Antimicrobial Chemotherapy, 2017, 72, 1462-1465.	3.0	38
65	Use of Dipeptidyl-Peptidase IV Inhibitors and Bullous Pemphigoid. Dermatology, 2017, 233, 401-403.	2.1	30
66	TUCUXI. , 2017, , .		13
67	Free and total plasma concentrations of elvitegravir/cobicistat during pregnancy and postpartum: A case report. Reproductive Toxicology, 2017, 72, 214-215.	2.9	0
68	N-acetyl-cysteine in a double-blind randomized placebo-controlled trial: Towards biomarker guided treatment in early psychosis. European Psychiatry, 2017, 41, s806-s806.	0.2	2
69	Lamotrigine serum levels: Ceiling effect in people with epilepsy in remission?. Epilepsy and Behavior, 2017, 74, 41-44.	1.7	11
70	Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	32
71	The levels of vancomycin in the blood and the wound after the local treatment of bone and soft-tissue infection with antibiotic-loaded calcium sulphate as carrier material. Bone and Joint Journal, 2017, 99-B, 1537-1544.	4.4	45
72	Trastuzumab versus MYL-1401O (a proposed trastuzumab biosimilar) in a phase I bioequivalence study: In vivo and in vitro immunomodulation.. Journal of Clinical Oncology, 2017, 35, 10-10.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Biases affecting injected doses of an experimental drug during clinical trials. <i>Trials</i> , 2016, 17, 321.	1.6	0
74	Comparison of Population Pharmacokinetics Based on Steady-State Assumption Versus Electronically Monitored Adherence to Lopinavir, Atazanavir, Efavirenz, and Etravirine: A Retrospective Study. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 506-515.	2.0	2
75	Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1933-1942.	3.0	13
76	Pregnancy outcome following maternal exposure to pregabalin may call for concern. <i>Neurology</i> , 2016, 86, 2251-2257.	1.1	75
77	Cascaded PID controller for anaesthesia delivery. , 2016, 2016, 533-536.		7
78	The emerging role of multiplex tandem mass spectrometry analysis for therapeutic drug monitoring and personalized medicine. <i>TrAC - Trends in Analytical Chemistry</i> , 2016, 84, 5-13.	11.4	29
79	Multigenerational effects of the anticancer drug tamoxifen and its metabolite 4-hydroxy-tamoxifen on <i>Daphnia pulex</i> . <i>Science of the Total Environment</i> , 2016, 545-546, 21-29.	8.0	29
80	Gentamicin Exposure and Sensorineural Hearing Loss in Preterm Infants. <i>PLoS ONE</i> , 2016, 11, e0158806.	2.5	31
81	Pharmacokinetics in hepatic impairment: Mind the protein binding. <i>Journal of Hepatology</i> , 2015, 63, 1539-1540.	3.7	2
82	Pregnancy Outcome Following Maternal Exposure to Mirtazapine. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 250-259.	1.4	32
83	Erlotinib. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 2-21.	2.0	36
84	In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid. <i>Drug Metabolism and Disposition</i> , 2015, 44, 151-161.	3.3	27
85	Pharmacokinetic modelling of dialytic clearance in a case of acyclovir intoxication. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 325-327.	2.5	2
86	Pediatric reference intervals for plasma free and total metanephrines established with a parametric approach: Relevance to the diagnosis of neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2015, 62, 587-593.	1.5	33
87	The anticancer drug metabolites endoxifen and 4-hydroxy-tamoxifen induce toxic effects on <i>Daphnia pulex</i> in a two-generation study. <i>Science of the Total Environment</i> , 2015, 520, 232-240.	8.0	24
88	Label-Free Detection of Tobramycin in Serum by Transmission-Localized Surface Plasmon Resonance. <i>Analytical Chemistry</i> , 2015, 87, 5278-5285.	6.5	115
89	Intermittent hemodialysis treatment in cefepime-induced neurotoxicity: Case report, pharmacokinetic modeling, and review of the literature. <i>Hemodialysis International</i> , 2015, 19, 333-343.	0.9	23
90	Therapeutic drug monitoring of targeted anticancer therapy. <i>Biomarkers in Medicine</i> , 2015, 9, 887-893.	1.4	24

#	ARTICLE	IF	CITATIONS
91	Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 1307-1319.	2.3	60
92	Perampanel: A Significant Liver Enzyme Inducer in Some Patients?. <i>European Neurology</i> , 2014, 72, 213-216.	1.4	10
93	Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 1090-1101.	2.4	50
94	Towards a new combination therapy for tuberculosis with next generation benzothiazinones. <i>EMBO Molecular Medicine</i> , 2014, 6, 372-383.	6.9	311
95	Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2489-2498.	3.0	31
96	High-throughput hydrophilic interaction chromatography coupled to tandem mass spectrometry for the optimized quantification of the anti-Gram-negatives antibiotic colistin A/B and its pro-drug colistimethate. <i>Journal of Chromatography A</i> , 2014, 1369, 52-63.	3.7	26
97	Tobramycin exposure from active calcium sulfate bone graft substitute. <i>BMC Pharmacology & Toxicology</i> , 2014, 15, 12.	2.4	7
98	Large-scale imatinib doseâ€“concentrationâ€“effect study in CML patients under routine care conditions. <i>Leukemia Research</i> , 2014, 38, 764-772.	0.8	37
99	Free and Total Plasma Levels of Lopinavir during Pregnancy, at Delivery and Postpartum: Implications for Dosage Adjustments in Pregnant Women. <i>Antiviral Therapy</i> , 2013, 18, 171-182.	1.0	31
100	Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients. <i>Malaria Journal</i> , 2013, 12, 235.	2.3	33
101	Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 1007-1018.	2.4	33
102	Benchmarking Therapeutic Drug Monitoring Software: A Review of Available Computer Tools. <i>Clinical Pharmacokinetics</i> , 2013, 52, 9-22.	3.5	141
103	Pharmacokinetic interaction between methotrexate and chloral hydrate. <i>Pediatric Blood and Cancer</i> , 2013, 60, 518-520.	1.5	10
104	Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2013, 120, 463-471.	2.3	94
105	Imatinib-induced dose-dependent interstitial lung disease successfully switched to nilotinib: a case report with concentration exposure data. <i>International Journal of Hematology</i> , 2013, 97, 299-300.	1.6	7
106	Multiplex Liquid Chromatography-Tandem Mass Spectrometry Assay for Simultaneous Therapeutic Drug Monitoring of Ribavirin, Boceprevir, and Telaprevir. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3147-3158.	3.2	22
107	Systematic Review of Population Pharmacokinetic Analyses of Imatinib and Relationships With Treatment Outcomes. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 150-167.	2.0	36
108	Pharmacovigilance in pregnancy: adverse drug reactions associated with fetal disorders. <i>Journal of Perinatal Medicine</i> , 2013, 41, 301-307.	1.4	4

#	ARTICLE	IF	CITATIONS
109	A Pain in the Neck. <i>Clinical Chemistry</i> , 2013, 59, 1280-1281.	3.2	2
110	Toxic and drug-induced peripheral neuropathies. <i>Current Opinion in Neurology</i> , 2013, 26, 481-488.	3.6	22
111	Authors' response to: Statins in pregnancy: safety and perspectives of therapeutic applications. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2013, 120, 1440-1440.	2.3	1
112	A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients. <i>Journal of Mass Spectrometry</i> , 2013, 48, 616-625.	1.6	45
113	Response to Diaz and de Leon "The Mathematics of Drug Dose Individualization Should be Built With Random Effects Linear Models". <i>Therapeutic Drug Monitoring</i> , 2013, 35, 873-874.	2.0	0
114	Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 9-18.	1.5	25
115	Safe and Effective Variability "A Criterion for Dose Individualization. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 565-568.	2.0	75
116	Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir in HIV-Positive and Healthy Individuals. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2959-2966.	3.2	39
117	Monoamine Oxidase A Down-Regulation Contributes to High Metanephrine Concentration in Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2773-2781.	3.6	25
118	Late onset tacrolimus-induced life-threatening polyneuropathy in a kidney transplant recipient patient. <i>CKJ: Clinical Kidney Journal</i> , 2012, 5, 323-326.	2.9	18
119	Dosage Optimization of Treatments Using Population Pharmacokinetic Modeling and Simulation. <i>Chimia</i> , 2012, 66, 291-295.	0.6	8
120	Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with <i>Aspergillus pneumonia</i> . <i>Aids</i> , 2012, 26, 776-778.	2.2	9
121	Prevalence and determinants of QT interval prolongation in medical inpatients. <i>Internal Medicine Journal</i> , 2012, 42, 933-940.	0.8	45
122	Pregnancy Outcome Following Exposure to Topical Retinoids: A Multicenter Prospective Study. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1844-1851.	2.0	48
123	Therapeutic Drug Monitoring of Imatinib. <i>Clinical Pharmacokinetics</i> , 2012, 51, 187-201.	3.5	43
124	Challenging Recommended Oral and Intravenous Voriconazole Doses for Improved Efficacy and Safety: Population Pharmacokinetics-Based Analysis of Adult Patients With Invasive Fungal Infections. <i>Clinical Infectious Diseases</i> , 2012, 55, 381-390.	5.8	178
125	An agenda for UK clinical pharmacology: Monitoring drug therapy. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 917-923.	2.4	27
126	Therapeutic Drug Monitoring of Targeted Anticancer Therapy. Tyrosine Kinase Inhibitors and Selective Estrogen Receptor Modulators: A Clinical Pharmacology Laboratory Perspective. , 2012, , 197-250.		2

#	ARTICLE	IF	CITATIONS
127	Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 609-622.	3.3	15
128	Who is in charge of assessing therapeutic drug monitoring? The case of imatinib. Lancet Oncology, The, 2011, 12, 9-11.	10.7	22
129	Development and Validation of Decision Rules to Guide Frequency of Monitoring CD4 Cell Count in HIV-1 Infection before Starting Antiretroviral Therapy. PLoS ONE, 2011, 6, e18578.	2.5	16
130	Successful Efavirenz Dose Reduction Guided by Therapeutic Drug Monitoring. Antiviral Therapy, 2011, 16, 189-197.	1.0	38
131	Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood, 2011, 117, e75-e87.	1.4	202
132	Systemic exposure to tobramycin after local antibiotic treatment with calcium sulphate as carrier material. Archives of Orthopaedic and Trauma Surgery, 2011, 131, 657-662.	2.4	45
133	How quickly should we titrate antihypertensive medication? Systematic review modelling blood pressure response from trial data. Heart, 2011, 97, 1771-1775.	2.9	22
134	Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration. Journal of Antimicrobial Chemotherapy, 2011, 66, 1573-1581.	3.0	25
135	Substance P-induced skin inflammation is not modulated by a single dose of sitagliptin in human volunteers. Biological Chemistry, 2011, 392, 217-21.	2.5	12
136	An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: First evidence of 4-hydroxylated metabolites in breast cancer patients. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 3402-3414.	2.3	35
137	New psycho-pedagogic approach to obesity treatment: A 5-year follow-up. Patient Education and Counseling, 2010, 79, 333-337.	2.2	21
138	Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients. BMC Infectious Diseases, 2010, 10, 2.	2.9	21
139	Imatinib plasma levels: correlation with clinical benefit in GIST patients. British Journal of Cancer, 2010, 102, 1198-1199.	6.4	35
140	Ganciclovir exposure under a 450-mg daily dosage of valganciclovir for cytomegalovirus prevention in kidney transplantation: a prospective study. Clinical Transplantation, 2010, 24, 794-800.	1.6	14
141	ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenetics and Genomics, 2010, 20, 217-230.	1.5	104
142	Diagnostic accuracy of free and total metanephrines in plasma and fractionated metanephrines in urine of patients with pheochromocytoma. European Journal of Endocrinology, 2010, 162, 951-960.	3.7	85
143	siRNA-Mediated Knock-Down of P-Glycoprotein Expression Reveals Distinct Cellular Disposition of Anticancer Tyrosine Kinases Inhibitors. Drug Metabolism Letters, 2010, 4, 114-119.	0.8	24
144	Oseltamivir in Seasonal, Avian H5N1 and Pandemic 2009 A/H1N1 Influenza. Clinical Pharmacokinetics, 2010, 49, 741-765.	3.5	48

#	ARTICLE	IF	CITATIONS
145	Rapid occurrence of depression following addition of sodium oxybate to modafinil. <i>Sleep Medicine</i> , 2010, 11, 500-501.	1.6	22
146	High Cefepime Plasma Concentrations and Neurological Toxicity in Febrile Neutropenic Patients with Mild Impairment of Renal Function. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4360-4367.	3.2	147
147	Referrals of Cancer versus Non-Cancer Patients to A Palliative Care Consult Team: Do They Differ?. <i>Journal of Palliative Care</i> , 2009, 25, 92-99.	1.0	12
148	Residual Antimalarials in Malaria Patients from Tanzania â€œ Implications on Drug Efficacy Assessment and Spread of Parasite Resistance. <i>PLoS ONE</i> , 2009, 4, e8184.	2.5	28
149	Reassessment of Recommended Imipenem Doses in Febrile Neutropenic Patients with Hematological Malignancies. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 785-787.	3.2	37
150	Population Pharmacokinetics of Ganciclovir in Solid-Organ Transplant Recipients Receiving Oral Valganciclovir. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3017-3023.	3.2	43
151	Angiotensin-Converting Enzyme and Dipeptidyl Peptidase IV Inhibitors. <i>Hypertension</i> , 2009, 54, 468-470.	2.7	25
152	Imipenem underdosing as a cause of persistent neutropenic fever?. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 665-667.	3.0	6
153	"Iatrogenicity cascade": Doing harm by treating harm?. <i>Wiener Medizinische Wochenschrift</i> , 2009, 159, 53-57.	1.1	0
154	The bioavailability of bromazepam, omeprazole and paracetamol given by nasogastric feeding tube. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 435-442.	1.9	9
155	A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 331-341.	2.3	5
156	Pharmacogenetics-Based Population Pharmacokinetic Analysis of Efavirenz in HIV-1-Infected Individuals. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 85, 485-494.	4.7	113
157	A LCâ€œtandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 1057-1069.	2.3	101
158	Adaptation of clinical practice guidelines on major depressive disorders in the general hospital: An update. <i>Journal of Psychosomatic Research</i> , 2009, 66, 353-354.	2.6	1
159	High imipenem blood concentrations associated with toxic encephalopathy in a patient with mild renal dysfunction. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 386-388.	2.5	15
160	Valganciclovir in Adult Solid Organ Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2009, 48, 399-418.	3.5	65
161	Antidepressants for the Treatment of Chronic Pain. <i>Drugs</i> , 2008, 68, 2611-2632.	10.9	173
162	Glutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients. <i>Neuropsychopharmacology</i> , 2008, 33, 2187-2199.	5.4	321

#	ARTICLE	IF	CITATIONS
163	Calibration of Fractionated Metanephrines in Urine: Still an Issue?. Clinical Chemistry, 2008, 54, 1738-1739.	3.2	3
164	Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. British Journal of Cancer, 2008, 98, 1633-1640.	6.4	106
165	Misleading tacrolimus concentration value in blood taken from a catheter used for tacrolimus administration. American Journal of Health-System Pharmacy, 2008, 65, 226-228.	1.0	7
166	Is Dipeptidylpeptidase IV the Missing Link in Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema?. Hypertension, 2008, 51, 45-47.	2.7	6
167	Disposition of valganciclovir during continuous renal replacement therapy in two lung transplant recipients. Journal of Antimicrobial Chemotherapy, 2008, 61, 1332-1335.	3.0	18
168	Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes. Clinical Infectious Diseases, 2008, 46, 201-211.	5.8	823
169	Determination of Unbound Antiretroviral Drug Concentrations by a Modified Ultrafiltration Method Reveals High Variability in the Free Fraction. Therapeutic Drug Monitoring, 2008, 30, 511-522.	2.0	47
170	Variability of Voriconazole Plasma Levels Measured by New High-Performance Liquid Chromatography and Bioassay Methods. Antimicrobial Agents and Chemotherapy, 2007, 51, 137-143.	3.2	94
171	Novel Starches. Anesthesiology, 2007, 106, 132-143.	2.5	12
172	NPY Y1 receptor is not involved in the hemodynamic response to an acute cold pressor test in mice. Peptides, 2007, 28, 315-319.	2.4	4
173	Gliptins. Lancet, The, 2007, 369, 269.	13.7	6
174	Oligoanalgesia in the Emergency Department: Short-Term Beneficial Effects of an Education Program on Acute Pain. Annals of Emergency Medicine, 2007, 50, 462-471.	0.6	98
175	Determination of aciclovir and ganciclovir in human plasma by liquid chromatography-spectrofluorimetric detection and stability studies in blood samples. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 852, 420-429.	2.3	43
176	Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels. Leukemia, 2007, 21, 1561-1562.	7.2	44
177	Reply to Zong et al.. Leukemia, 2007, 21, 1563-1564.	7.2	2
178	Effect of dronedarone on renal function in healthy subjects. British Journal of Clinical Pharmacology, 2007, 64, 070727055311005-???	2.4	96
179	Impact of the C2/C6 Ratio of High-molecular-weight Hydroxyethyl Starch on Pharmacokinetics and Blood Coagulation in Pigs. Anesthesiology, 2007, 107, 442-451.	2.5	7
180	34 Pharmacokinetic and pharmacodynamic evaluation of valganciclovir in solid organ transplant patients. International Journal of Infectious Diseases, 2006, 10, S19.	3.3	0

#	ARTICLE	IF	CITATIONS
181	A case of voluntary intoxication with efavirenz and lamivudine. <i>Aids</i> , 2006, 20, 1352-1354.	2.2	6
182	Effect of High- and Low-molecular-weight Low-substituted Hydroxyethyl Starch on Blood Coagulation during Acute Normovolemic Hemodilution in Pigs. <i>Anesthesiology</i> , 2006, 105, 1228-1237.	2.5	29
183	Are Plasma Levels Valid Surrogates for Cellular Concentrations of Antiretroviral Drugs in HIV-infected Patients?. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 332-338.	2.0	19
184	Population pharmacokinetics of imatinib and the role of alpha1-acid glycoprotein. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 97-112.	2.4	161
185	Orosomucoid (α 1-acid glycoprotein) plasma concentration and genetic variants: Effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 307-318.	4.7	66
186	Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomized, crossover placebo-controlled trial. <i>Clinical Nutrition</i> , 2006, 25, 418-427.	5.0	72
187	Population Pharmacokinetics of Atazanavir in Patients with Human Immunodeficiency Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3801-3808.	3.2	82
188	Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures. <i>Antiviral Therapy</i> , 2006, 11, 53-62.	1.0	6
189	Ritonavir-Boosted Atazanavir-Lopinavir Combination: A Pharmacokinetic Interaction Study of Total, Unbound Plasma and Cellular Exposures. <i>Antiviral Therapy</i> , 2006, 11, 53-62.	1.0	28
190	Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 1-5.	1.5	355
191	Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 599-608.	1.5	73
192	Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 819, 259-276.	2.3	100
193	The importance of assessing the dose actually administered in pharmacokinetic trials. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, 235-240.	4.7	5
194	Effect of dronedarone on renal function in healthy subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, P10-P10.	4.7	3
195	Two cases of "cannabis acute psychosis" following the administration of oral cannabis. <i>BMC Psychiatry</i> , 2005, 5, 17.	2.6	74
196	Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. <i>European Journal of Clinical Pharmacology</i> , 2005, 60, 865-873.	1.9	70
197	Assessment of Driving Capability Through the Use of Clinical and Psychomotor Tests in Relation to Blood Cannabinoids Levels Following Oral Administration of 20 mg Dronabinol or of a Cannabis Decoction Made with 20 or 60 mg Δ^9 -THC*. <i>Journal of Analytical Toxicology</i> , 2005, 29, 327-338.	2.8	72
198	Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, 269-270.	3.0	43

#	ARTICLE	IF	CITATIONS
199	Population Pharmacokinetics of Indinavir in Patients Infected with Human Immunodeficiency Virus. Antimicrobial Agents and Chemotherapy, 2004, 48, 3226-3232.	3.2	36
200	Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients. Clinical Cancer Research, 2004, 10, 3728-3736.	7.0	403
201	Oral administration of a low dose of midazolam (75µg) as an in vivo probe for CYP3A activity. European Journal of Clinical Pharmacology, 2004, 60, 237-46.	1.9	89
202	Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. European Journal of Clinical Pharmacology, 2004, 60, 231-6.	1.9	82
203	Determination of imatinib (Gleevec®) in human plasma by solid-phase extraction followed by liquid chromatography-ultraviolet absorbance detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 803, 285-292.	2.3	52
204	Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clinical Pharmacology and Therapeutics, 2004, 75, 13-33.	4.7	781
205	The bradykinin antagonist icatibant increases electrolyte and water excretion after sodium challenge in patients with liver cirrhosis. Clinical Pharmacology and Therapeutics, 2004, 75, P12.	4.7	1
206	Pharmacokinetic and pharmacodynamic profile of icatibant. Clinical Pharmacology and Therapeutics, 2004, 75, P56.	4.7	2
207	Icatibant has no impact on renal function in healthy subjects. Clinical Pharmacology and Therapeutics, 2004, 75, P57.	4.7	0
208	CYP3A activity measured by the midazolam test is not related to 3435 C>T polymorphism in the multiple drug resistance transporter gene. Pharmacogenetics and Genomics, 2004, 14, 255-260.	5.7	30
209	Molecular and clinical determinants of drug-induced long QT syndrome: an iatrogenic channelopathy. Swiss Medical Weekly, 2004, 134, 685-94.	1.6	36
210	Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clinical Pharmacology and Therapeutics, 2003, 73, 20-30.	4.7	231
211	Major depressive disorder in the general hospital: adaptation of clinical practice guidelines. General Hospital Psychiatry, 2003, 25, 185-193.	2.4	27
212	NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios. British Journal of Clinical Pharmacology, 2003, 55, 62-67.	2.4	22
213	Pharmacokinetics and Dosage Adaptation of Meropenem during Continuous Venovenous Hemodiafiltration in Critically Ill Patients. Journal of Clinical Pharmacology, 2003, 43, 1329-1340.	2.0	67
214	Composition and Cost of Drugs Stored at Home by Elderly Patients. Annals of Pharmacotherapy, 2003, 37, 731-737.	1.9	27
215	Functional consequence of MDR1 expression on imatinib intracellular concentrations. Blood, 2003, 102, 1142-1142.	1.4	66
216	Transplacental passage of protease inhibitors at delivery. Aids, 2002, 16, 889-893.	2.2	102

#	ARTICLE	IF	CITATIONS
217	Population Pharmacokinetic-Pharmacodynamic Modelling of Angiotensin Receptor Blockade in Healthy Volunteers. <i>Clinical Pharmacokinetics</i> , 2002, 41, 137-152.	3.5	18
218	Interindividual Variability of the Clinical Pharmacokinetics of Methadone. <i>Clinical Pharmacokinetics</i> , 2002, 41, 1153-1193.	3.5	510
219	Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. <i>Lancet, The</i> , 2002, 359, 30-36.	13.7	635
220	Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction: application for the assessment of their transplacental passage at delivery. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002, 774, 127-140.	2.3	44
221	Determination of meropenem in plasma and filtrate-dialysate from patients under continuous veno-venous haemodiafiltration by SPE-LC. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2002, 29, 17-33.	2.8	25
222	Bioavailability and Biological Efficacy of a New Oral Formulation of Salmon Calcitonin in Healthy Volunteers. <i>Journal of Bone and Mineral Research</i> , 2002, 17, 1478-1485.	2.8	79
223	Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients. <i>Aids</i> , 2002, 16, 1982-1983.	2.2	28
224	Rate, type, and cost of adverse drug reactions in emergency department admissions. <i>European Journal of Internal Medicine</i> , 2001, 12, 442-447.	2.2	59
225	A preliminary evaluation of the discriminative power of the monoethylglycinexylidide formation test after intravenous and oral administration of lidocaine. <i>Transplantation Proceedings</i> , 2001, 33, 2557-2562.	0.6	2
226	Disappearance Rate of Catecholamines, Total Metanephrines, and Neuropeptide Y from the Plasma of Patients after Resection of Pheochromocytoma. <i>Clinical Chemistry</i> , 2001, 47, 1075-1082.	3.2	65
227	Nelfinavir Plasma Levels Under Twice-Daily and Three-Times-Daily Regimens: High Interpatient and Low Inpatient Variability. <i>Therapeutic Drug Monitoring</i> , 2001, 23, 394-398.	2.0	52
228	Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. <i>Aids</i> , 2001, 15, 71-75.	2.2	743
229	Diet Acids and Alkalis Influence Calcium Retention in Bone. <i>Osteoporosis International</i> , 2001, 12, 493-499.	3.1	205
230	Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients. <i>European Journal of Clinical Pharmacology</i> , 2001, 57, 723-727.	1.9	20
231	δ^9 -THC, 11-OH- δ^9 -THC and δ^9 -THCCOOH plasma or serum to whole blood concentrations distribution ratios in blood samples taken from living and dead people. <i>Forensic Science International</i> , 2001, 123, 159-164.	2.2	102
232	'Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients'. <i>Aids</i> , 2001, 15, 1193-1194.	2.2	18
233	Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction. <i>Biomedical Applications</i> , 2000, 740, 43-58.	1.7	99
234	Type 1 IFNs in human versus mouse. <i>Nature Immunology</i> , 2000, 1, 265-265.	14.5	1

#	ARTICLE	IF	CITATIONS
235	Bioavailability of repeated oral administration of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase in healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 2000, 55, 749-754.	1.9	12
236	Psychopharmacology in supportive care of cancer: a review for the clinician. <i>Supportive Care in Cancer</i> , 2000, 8, 89-97.	2.2	35
237	Pharmacokinetics and Pharmacodynamics of IFN- γ 1a in Healthy Volunteers. <i>Journal of Interferon and Cytokine Research</i> , 2000, 20, 857-866.	1.2	87
238	Trace lithium in mood disorders. <i>Journal of Affective Disorders</i> , 1999, 54, 199-203.	4.1	4
239	Influence of interferon γ 1a dose frequency on PBMC cytokine secretion and biological effect markers. <i>Journal of Neuroimmunology</i> , 1999, 99, 131-141.	2.3	94
240	The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: A randomized double-blind controlled trial. <i>Annals of Oncology</i> , 1999, 10, 1511-1514.	1.2	142
241	Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100 240, on endocrine and renal functions in healthy volunteers. <i>Journal of Hypertension</i> , 1999, 17, 427-437.	0.5	30
242	Pharmacokinetic Consequences of a Citalopram Treatment Discontinuation. <i>Therapeutic Drug Monitoring</i> , 1999, 21, 263.	2.0	9
243	Inhibition of CYP2E1 by chlormethiazole as measured by chlorzoxazone pharmacokinetics in patients with alcoholism and in healthy volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 64, 52-57.	4.7	29
244	Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 42, 433-440.	2.3	62
245	Estimation of Glomerular Filtration Rate by Sinistrin Clearance Using Various Approaches. <i>Renal Failure</i> , 1998, 20, 267-276.	2.1	9
246	Specific Determination of PAH and Its N-Acetyl Metabolite by HPLC Increases the Accuracy and Precision of PAH Clearance Measurements. <i>Renal Failure</i> , 1998, 20, 311-317.	2.1	2
247	Effects of MDL 100,240, a Dual Inhibitor of Angiotensin-Converting Enzyme and Neutral Endopeptidase on the Vasopressor Response to Exogenous Angiotensin I and Angiotensin II Challenges in Healthy Volunteers. <i>Journal of Cardiovascular Pharmacology</i> , 1998, 31, 408-417.	1.9	14
248	Characterization of a Selective Antagonist of Neuropeptide Y at the Y2 Receptor. <i>Journal of Biological Chemistry</i> , 1997, 272, 7699-7706.	3.4	55
249	Sinistrin Clearance for Determination of Glomerular Filtration Rate: A Reappraisal of Various Approaches Using a New Analytical Method. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 679-692.	2.0	33
250	Pharmacokinetic-Pharmacodynamic Profile of Angiotensin II Receptor Antagonists. <i>Clinical Pharmacokinetics</i> , 1997, 32, 1-29.	3.5	82
251	Spectrophotometric determination of methylene blue in biological fluids after ion-pair extraction and evidence of its adsorption on plastic polymers. <i>European Journal of Pharmaceutical Sciences</i> , 1997, 5, 335-345.	4.0	21
252	High-performance liquid chromatography of the renal blood flow marker p-aminohippuric acid (PAH) and its metabolite N-acetyl PAH improves PAH clearance measurements. <i>Biomedical Applications</i> , 1997, 703, 25-36.	1.7	16

#	ARTICLE	IF	CITATIONS
253	Safety of oral immunisation with recombinant urease in patients with <i>Helicobacter pylori</i> infection. <i>Lancet</i> , The, 1996, 347, 1630-1631.	13.7	72
254	Influence of perinatal, developmental and environmental factors on cognitive abilities of preterm children without major impairments at 5 years. <i>Early Human Development</i> , 1995, 43, 151-164.	1.8	73
255	Influence of Quinidine on the Pharmacokinetics of Trimipramine and on Its Effect on the Waking EEG of Healthy Volunteers. <i>Neuropsychobiology</i> , 1992, 25, 214-220.	1.9	16
256	The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 1992, 43, 441-443.	1.9	13
257	Absence of metabolic effects of the topical carbonic anhydrase inhibitors MK-927 and sezolamide during two-week ocular administration to normal subjects. <i>Clinical Pharmacology and Therapeutics</i> , 1991, 49, 665-673.	4.7	12
258	Right arm involvement and pain extension can help to differentiate coronary diseases from chest pain of other origin: a prospective emergency ward study of 278 consecutive patients admitted for chest pain. <i>Journal of Internal Medicine</i> , 1990, 227, 165-172.	6.0	46
259	The effect of rectal and nasal administration of salmon calcitonin in normal subjects. <i>Calcified Tissue International</i> , 1987, 41, 252-258.	3.1	88
260	Evaluation of Exposure to Vancomycin in Neonates with Current Dosing Approaches. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
261	Valproate in status epilepticus: Correlation between loading dose, serum levels, and clinical response. <i>European Journal of Neurology</i> , 0, , .	3.3	4